Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olorofim versus AmBisome followed by standard of care for invasive aspergillosis
NL-OMON56006Phase 3Recruiting
- Sponsor
- F2G
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in invasive aspergillosis (IA) and aspergillosis comparing Olorofim with AmBisome followed by standard of care (2 arms). Primary endpoint: All-cause mortality at Day 42. Started Jul 2023; status: recruiting.
02
Drugs
olorofimamphotericin b
03
Conditions
invasive aspergillosis (IA)aspergillosis
Beyond the preview
Go deeper on NL-OMON56006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56006.